Vitamin D (VitD) deficiency is common in patients with hematologic malignancies undergoing allogeneic transplantation (alloSCT), but its prognostic relevance is unclear.
Vitamin D (VitD) deficiency is common in patients with hematologic malignancies undergoing allogeneic transplantation (alloSCT), but its prognostic relevance is unclear.
Patients and Methods
The impact of pretransplant VitD status on overall survival, relapse mortality, and nonrelapse mortality was investigated retrospectively in a cohort of 492 patients undergoing alloSCT at our center from 2002 to 2013. VitD deficiency was defined as a serum level of 25-hydroxyvitamin D3 , 20 ng/mL (equivalent to , 50 nM) before alloSCT and was assessed using accredited laboratory methods and a standard chemiluminescent immunoassay. Results were validated in an independent cohort of 398 patients diagnosed with myeloid malignancies.
Results
A total of 396 (80%) and 348 (87%) patients had VitD deficiency before alloSCT in the training and validation cohort, respectively. In the training cohort, VitD deficiency was significantly associated with inferior overall survival (hazard ratio [HR], 1.78; P = .007) in multivariable analysis. This was due to a higher risk of relapse (HR, 1.96; P = .006) rather than nonrelapse mortality. A significant association of pretransplant VitD deficiency with higher relapse rates was observed only in patients diagnosed with myeloid (HR, 2.55; P = .014) but not with lymphatic diseases (HR, 1.60; P = .147).
A similar impact of pretransplant VitD deficiency on relapse risk in myeloid diseases was also observed in an independent patient cohort (HR, 2.60; P = .017). Validation of the effect of VitD deficiency on relapse in patients with myeloid malignancies was successful.
INTRODUCTION
Allogeneic stem cell transplantation (alloSCT) represents a uniquely curative treatment modality for patients with high-risk hematologic malignancies. Major challenges to the success of alloSCT are treatment-related complications and disease recurrence. Vitamin D (VitD), a fat-soluble steroid hormone, is a central regulator of calcium and phosphate metabolism, maintaining bone homeostasis and promoting bone and overall health. [1] [2] [3] On the cellular level, binding of VitD to its nuclear receptor has been shown to affect multiple signaling pathways controlling proliferation, apoptosis, differentiation, angiogenesis, and metastasis. 2 Furthermore, VitD has been shown to exert potent modulatory effects in both innate and adaptive immune responses 2, 4 and, in the context of alloSCT, to be implicated in the development of graft-versushost disease (GVHD). 5, 6 A compromised VitD status is a common finding all over the world, affecting not only medical inpatients but also the general population. 3, 7, 8 Measurements of serum 25-hydroxyvitamin D3 (25D3) levels, the major circulating VitD metabolite, are commonly used to assess wholebody VitD status and identify individual VitD adequacy or insufficiency. 3 Patients with hematopoietic malignancies undergoing alloSCT are particularly at increased risk for VitD deficiency. Possible reasons include prolonged hospitalization, active sunlight avoidance, and poor nutritional status. Accordingly, in several studies, a high incidence of VitD deficiency was found before as well as after alloSCT. [9] [10] [11] However, the prognostic impact of the pretransplant VitD status has not been fully delineated. In this study, we therefore evaluated the impact of pretransplant VitD status on major clinical outcome parameters after alloSCT.
PATIENTS AND METHODS

Patients
Patients allografted for myeloid and lymphoid malignancies were eligible for this study if they had undergone alloSCT at our center (University Hospital Heidelberg, Germany) between 2002 and 2013 (training cohort) and serum samples available for measurement of pretransplant 25D3 levels. The validation cohort consisted of patients diagnosed with acute myeloid leukemia and myelodysplastic syndromes who underwent allografting at the Department of Bone Marrow Transplantation of the University Hospital Essen (Germany) between 2009 and 2013 and had serum samples available for measurement of pretransplant 25D3 levels. Written informed consent according to the Declaration of Helsinki was obtained for all patients, and the local ethics committee approved the sample and data collection. Patient data were obtained from medical records and chart review. Disease stage before alloSCT was assessed applying published criteria. 12 Transplantation Procedure, GVHD Prophylaxis, and Supportive Care
AlloSCT was performed according to local standard operating procedures. GVHD prophylaxis and supportive care were performed as previously described. 13, 14 Acute GVHD was clinically and histologically diagnosed and graded using standard criteria and as reported previously. [13] [14] [15] Chronic GVHD was diagnosed according to published criteria. 16 Relapse of the original malignancy was assessed according to standardized published criteria. Individual VitD status was neither assessed before alloSCT nor treated routinely. At the time of serum sample collection and before, none of the patients received VitD substitution treatment.
Blood and Serum Analyses
Blood counts and donor chimerism data (assessed in peripheral blood and/or bone marrow) were obtained from medical records. Serum samples were collected between 0 and 2 months before alloSCT and cryopreserved at 280°C. Serum levels of 25D3 were quantified in the first serum sample before start of conditioning treatment. For quantification of 25D3, a standard, commercially available chemiluminescent immunoassay (Liaison 25-OHVitamin D total; DiaSorin Deutschland, Dietzenbach, Germany) was applied as described previously. 17 All measurements were carried out using accredited laboratory methods at the Department of Clinical Chemistry of the Heidelberg University Hospital (certified according to International Organization for Standardization 15189 by Germany's national accreditation body).
Statistical Analysis
Categorical data of patient characteristics were compared using the x 2 test. Continuous variables were compared applying the Kruskal-Wallis test. Pretransplant VitD deficiency was defined as serum 25D3 level , 20 ng/mL (corresponding to , 50 nmol/L) in accordance with the literature. 3, [18] [19] [20] Distributions of survival times were estimated using the method of Kaplan and Meier. In case of competing events, the cumulative incidence of relapse and nonrelapse mortality (ie, death in absence of prior relapse; NRM) were estimated using the Aalen-Johansen estimator. 21 The CI estimation was performed using Greenwood's formula for the variance of the survival function and an extension of Greenwood's formula for the variance estimation of cumulative incidence. 22 The follow-up times were calculated by the reverse Kaplan-Meier estimate. 23 Overall survival (OS), incidence of relapse, and NRM were calculated from the date of alloSCT to the appropriate end point. Cox proportional hazards regression analysis was applied for OS. Relapse and NRM were considered as competing risk events and were analyzed by a cause-specific Cox model. Prognostic impact of pretransplant VitD deficiency on OS, relapse, and NRM was evaluated on the basis of hazard ratios (HRs) with 95% CIs from corresponding Cox models. Multivariable (cause-specific) Cox regression models were used to adjust effects for additional covariables: type of malignancy, disease stage, conditioning intensity, patient age, donor type, and recipient/donor sex match. The cumulative incidence of acute GVHD grade 1 to 2, acute GVHD grade 3 to 4 of the training and validation cohort, and chronic GVHD (training cohort) were calculated using competing risks analysis (cause-specific hazards models with relapse and death as competing events).
The effect of pretransplant VitD deficiency on relapse risk was evaluated in an independent cohort (University Hospital Essen; n = 398). To confirm and validate pretransplant VitD deficiency as a risk factor for relapse in patients with myeloid diseases, the Cox model was fitted to the validation data, including an offset that was equal to the effect of VitD deficiency in the model on the basis of patients with myeloid diseases from the training cohort. That means that the effect of VitD deficiency was transferred to the model for the validation cohort. The effect of VitD deficiency on relapse was estimated in addition to this transferred effect to verify whether the effect in the validation cohort differed from what had been observed in the training cohort. For a detailed description of the validation method, see Statistical Methods in the Appendix (online only).
Calculations were performed using the statistical software environment R (version 3.2.2), together with the R packages survival (version 2.38-3), mstate (version 0.2.9), cmprsk (version 2.2-7), and pec (version 2.4.7). All statistical tests were two-sided. HRs were estimated with 95% CIs. Values of P , .05 were considered statistically significant.
RESULTS
Patient Characteristics
A total of 492 patients who underwent alloSCT at the Heidelberg center met the eligibility criteria and were included in the training cohort; 398 patients transplanted at the Essen center were included in the validation cohort. Patient, disease, and transplant characteristics of the training and the validation cohort are listed in Table 1 . Estimated median follow-up was 51.2 months (95% CI, 47.5 to 57.3 months; range, 0.1 to 126.3 months) for the training cohort and 51.3 months (95% CI, 47.5 to 54 months; range, 0.0 to 81.2 months) for the validation cohort.
Pretransplant VitD Status and Baseline Patient and Treatment Characteristics
Median pretransplant 25D3 serum level was 11.8 ng/mL (range, 4.0 to 46.3 ng/mL) in the training cohort. A total of 396 patients (80%) displayed VitD deficiency before alloSCT. Baseline demographic, disease, and treatment characteristics did not significantly differ between the VitD groups (pretransplant VitD , 20 ng/mL v VitD $ 20 ng/mL) in the training cohort except for age, which was lower in VitD-deficient patients (53 v 55 years; Table 1 ). In the validation cohort, the median pretransplant 25D3 level was 10.5 ng/mL (range, 4.0 to 39.2 ng/mL), with a total of 348 patients (87%) being VitD deficient before alloSCT. Similarly, in the validation cohort, there was no difference between the VitD groups regarding patient and treatment characteristics. However, significantly fewer patients with pretransplant VitD deficiency had highrisk disease before alloSCT (P = 0.028; Table 1 ).
Pretransplant VitD Status and GVHD Incidence, Chimerism, and Immune Recovery
The cumulative incidence of acute GVHD grade 1 to 2, acute GVHD grade 3 to 4 (both on day +100 post-transplant), and chronic GVHD at +1 year post-transplant are listed in Table 1 . The corresponding stacked plots for acute GVHD and chronic GVHD (training cohort) and acute GVHD (validation cohort) were depicted in the Appendix ( Figs 1A, 1B, and 1C ). In the training cohort, VitD deficiency had no significant impact on the cumulative incidence of acute and chronic GVHD. However, in Time Since Transplantation (years) Fig 1. Impact of pretransplant vitamin D (VitD) status on overall survival, cumulative incidence of relapse, and nonrelapse mortality (NRM) after allogeneic stem cell transplantation in the training cohort. (A) In the entire training cohort (n = 492), estimated probability of overall survival at 2 years after allogeneic stem cell transplantation for VitD-deficient patients was 64.6% (95% CI, 60.0% to 69.5%) compared with 79.0% (95% CI, 71.2% to 87.6%) for patients with sufficient VitD levels (hazard ratio [HR], 1.92; 95% CI, 1.26 to 2.92; P = .002). (B) The cumulative incidence of relapse was 30% in 2 years (95% CI, 29.9% to 30.2%) in VitD-deficient patients as opposed to 17.8% (95% CI, 17.6% to 18.1%) in patients showing sufficient pretransplant VitD levels (HR, 2.04; 95% CI, 1.28 to 3.26; P = .003). (C) In contrast, the cumulative incidence of death without disease relapse in VitD-deficient versus VitD-sufficient patients was 14% in 2 years (95% CI, 13.9% to 14.1%) versus 9.5% (95% CI, 9.3% to 9.6%; HR, 1.77; 95% CI, 0.96 to 3.26; P = .068). (D) In the subgroup of patients diagnosed with myeloid diseases in the training cohort (n = 242), the cumulative incidence of relapse in VitD-deficient patients was 29.3% in 2 years (95% CI, 29.1% to 29.6%) and 14.8% in 2 years (95% CI, 14.5% to 15.1%) in VitD-sufficient patients (HR, 2.38; 95% CI, 1.18 to 4.79; P = .015). (E) The cumulative incidence of NRM was 14.9% in 2 years (95% CI, 14.7% to 15.1%) in VitD-deficient patients versus 11.3% in 2 years (95% CI, 11.0% to 11.6%) in VitD-sufficient patients (HR, 1.50; 95% CI, 0.69 to 3.23; P = .303) in the subgroup of patients diagnosed with myeloid diseases (n = 242). (F) In the subgroup of patients diagnosed with lymphatic diseases in the training cohort (n = 250), the cumulative incidence of relapse in VitD-deficient patients was 30.7% in 2 years (95% CI, 30.5% to 30.9%) compared with 21.7% in 2 years (95% CI, 21.2% to 22.1%) in patients showing sufficient pretransplant VitD levels (HR, 1.76; 95% CI, 0.94 to 3.31, P = .080). (G) The cumulative incidence of NRM in VitD-deficient patients was 13.2% in 2 years (95% CI, 13.0% to 13.3%) compared with 7.1% in 2 years (95% CI, 6.9% to 7.4%) in patients showing sufficient pretransplant VitD levels (HR, 2.36; 95% CI, 0.84 to 6.63; P = .104). Note: HR and P values were derived from univariable Cox models. the validation cohort, there was a trend toward a lower incidence of grade 3 to 4 acute GVHD in patients displaying VitD deficiency before alloSCT (HR, 0.56; P = .081). Rates of full donor chimerism and lymphocyte counts on day +28 and +100 postalloSCT did not significantly differ between the VitD groups in the training cohort (Table 1) . Further analysis of lymphocyte subsets was not feasible.
Impact of Pretransplant VitD Status on Outcome
By multivariable analysis, in the training cohort, pretransplant VitD deficiency was significantly associated with a higher relapse risk (HR, 1.96; P = .006) and inferior survival (HR, 1.78; P = .007) and also showed a trend toward a higher NRM risk (HR, 1.72; P = .088; Table 2 ). Other significant adverse factors were intermediate-stage disease (for OS and relapse risk), late-stage disease (for OS, relapse risk, and NRM), myeloid malignancy (for OS), and increasing age (for NRM). Estimated probability of survival and cumulative incidence of relapse and NRM in VitD-deficient versus VitD-sufficient patients of the training cohort are depicted in Figures 1A, 1B , and 1C.
Because myeloid malignancy was associated with worse OS (Table 2) , outcome parameters were analyzed separately in patients undergoing transplantation for myeloid (n = 228) and lymphoid (n = 249; only complete cases) malignancies. Similar to the entire training cohort, in patients with myeloid malignancies, pretransplant VitD deficiency was associated with a higher risk of relapse, overall mortality, and NRM, respectively, which was, however, significant only for relapse (HR, 2.55; P = .014; Table 3 ). In patients who underwent transplantation for lymphoid diseases, VitD deficiency was not a significant risk factor for relapse. However, VitD deficiency was associated with a trend toward higher NRM (HR, 2.55; P = .078) and a significantly inferior OS (HR, 2.06; P = .031; Table 3 ). The cumulative incidence of relapse and NRM in VitD-deficient versus VitD-sufficient patients of the training cohort allografted for myeloid and lymphoid malignancies is shown in Figures 1D, 1E, 1F , and 1G. The association of pretransplant VitD deficiency with a significantly increased risk of relapse but not of NRM in patients allografted for myeloid malignancies could also be observed in the validation cohort (Table 4 ; Figs 2A and 2B) . However, in the validation cohort, the effect of VitD deficiency on relapse risk did not translate into an OS disadvantage.
Regarding the validation, the HR for the effect of VitD deficiency estimated in addition to the offset (equal to the effect of VitD deficiency in the model on the basis of patients with myeloid diseases from the training cohort) was not significantly different from 1 (HR, 0.72; 95% CI, 0.33 to 1.56; P = .408). This means the effect of VitD deficiency in the validation cohort was not significantly different from the effect in the training set; thus, the HR of approximately 2.6 for the effect of pretransplant VitD deficiency on relapse risk in patients allografted for myeloid malignancies can be considered validated. Furthermore, the prediction ability is about the same if the effect of VitD deficiency has been newly estimated or transferred from the training cohort to the model via an offset. The corresponding prediction error plot is shown in Figure 2C .
DISCUSSION
VitD deficiency is frequent among patients with cancer and has been associated with poor prognosis of various solid as well as Abbreviations: HR: hazard ratio; MAC: myeloablative conditioning; NRM, nonrelapse mortality; OS, overall survival; RIC: reduced intensity conditioning; VitD: vitamin D (25D3).
*Acute myeloid leukemia, myelodysplastic and myeloproliferative syndrome. †Acute lymphatic leukemia, chronic lymphocytic leukemia, lymphoma and multiple myeloma. ‡Cause-specific hazards from a competing risks analysis for relapse and NRM. §According to Gratwohl et al. hematologic malignancies. 18, 19, [26] [27] [28] [29] [30] In a recent meta-analysis on the basis of 25 studies on various cancer types and more than 17,000 patients, higher circulating 25D3 levels at or near the time of diagnosis were independently associated with improved OS, reduced cancer-specific mortality, and better disease-free survival. 19 Interestingly, the effects on survival seem to be not restricted to patients with cancer, because in the general population, an association between VitD deficiency and increased risk of allcause mortality could be observed as well. 31 In the setting of alloSCT, pretransplant VitD deficiency is highly prevalent, affecting 70% to 90% of patients.
11, 32 In keeping with these reports, in our study, the prevalence of VitD deficiency according to the 20 ng/mL cutoff was similarly high (80% to 87%) and was substantially higher compared with the general German population (approximately 60%). 33 Despite several smaller studies suggesting that insufficient VitD levels are likely to harm patients undergoing alloSCT, data on the prognostic relevance of the pretransplant VitD status and its impact on clinical outcome parameters are sparse. 34, 35 VitD is a potent regulator of immune responses. 2, 3 In preclinical transplant models, VitD reduced the adverse effects of GVHD by lowering dendritic cell dependent stimulation of alloreactive lymphocytes. Validation of the effect of pretransplant vitamin D (VitD) deficiency in patients allografted for myeloid malignancies (validation cohort, n = 398). (A) In patients allografted for myeloid diseases, the cumulative incidence of relapse in VitD-deficient patients was 27.0% in 2 years (95% CI, 26.9% to 27.2%) and 10.0% in 2 years (95% CI, 9.7% to 10.3%) in VitD-sufficient patients (HR, 2.45; 95% CI, 1.14 to 5.26; P = .022). (B) In contrast, the cumulative incidence of nonrelapse mortality (NRM) in VitDdeficient versus VitD-sufficient patients was 27.9% in 2 years (95% CI, 27.7% to 28.0%) versus 32.0% in 2 years (95% CI, 31.6% to 32.4%; hazard ratio [HR], 0.78; 95% CI 0.48 to 1.24; P = .288). Note: HR and P values were derived from univariable Cox models. (C) Prediction error analysis showing superimposition of the prediction error curves for three different models. VitD trained and VitD trained on myeloid refer to a model including the effect of VitD deficiency as an offset. The parameter estimate for the effect results from the model on the basis of the full training data set or on the subset of patients with myeloid diseases, respectively. New refers to the model for which the effect of VitD deficiency has been estimated directly on the basis of the validation data set. For the estimation of the prediction error, 1,000 bootstrap subsamples of 252 observations each (corresponding 63.2% of the number of patients in the validation data set) were drawn from the validation data set and for each subsample. Because bootstrap subsamples are drawn from the validation data set and survival probabilities as well as the time-dependent prediction error are estimated for all event times that are contained in the validation data set, the resulting prediction error curve is a step function with jumps at every event time in the validation data set (cf Sauerbrei et al 25 ) . For a detailed description of the validation method, see also Statistical Methods (Appendix).
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Furthermore, several smaller clinical studies demonstrated beneficial effects against GVHD showing an improvement of chronic GVHD symptoms after VitD treatment. 6, 36 In the current study, pretransplant VitD deficiency had no significant impact on GVHD incidence. In the training set, advanced disease stage was associated with worse survival and with higher risk of both relapse and NRM. Notably, pretransplant VitD deficiency was also associated with inferior survival. This was due to higher risk of relapse rather than NRM, particularly in patients allografted for myeloid malignancies. In the validation cohort, the adverse impact of pretransplant VitD deficiency on the relapse risk was similar, whereas advanced disease stage was associated only with a modest and insignificant increase of relapse incidence in the multivariable model. This discrepancy may be partly explained by the fact that NRM as a competing risk to relapse was significantly affected by disease stage and much more pronounced in the validation set, and thus may have overrun the impact of disease stage on relapse. Furthermore, in the validation cohort, the beneficial effect of VitD on relapse risk did not fully translate into an OS advantage. To this end, it should be noted that OS represents a composite end point that is not only determined by relapse incidence, but also by NRM and postrelapse interventions (donor lymphocyte infusion treatment, availability of novel agents, etc.), which may be independent of VitD levels.
The growth inhibitory, prodifferentiation, and proapoptotic effects of VitD in vitro are well recognized, and low VitD levels have been shown to enhance clonal proliferation of leukemic cells. 4 Therefore, with regard to treatment before alloSCT but also to conditioning, one might speculate that VitD deficiency facilitates resistance to chemotherapy. In keeping with this, VitD deficiency has been demonstrated to be associated with shorter overall and relapse-free survival in patients treated for acute myeloid leukemia and myelodysplastic syndromes outside the context of alloSCT. 17, 18 With regard to the potent immunomodulatory effects of VitD, modulation and control of tumor immune escape by VitD and related pathways might also be of relevance. 2, 37 In the context of alloSCT, sufficient VitD levels might promote more aggressive surveillance of residual disease and more pronounced graft-versusleukemia activity resulting in less frequent disease recurrence. However, in this case, VitD deficiency could be expected to result in impaired immune recovery, lower lymphocyte counts, and less frequent full donor chimerism after alloSCT, which was not observed in our series. In a recent report on 123 children undergoing alloSCT, Hansson et al 34 showed that sufficient pretransplant VitD levels were associated with significantly lower relapse rates and improved survival only in children transplanted for malignancies. Similarly, no effects of VitD deficiency on immune reconstitution were discernible. By contrast, in another small study primarily focusing on chronic GVHD incidence in 53 adult patients, no differences with regard to relapse-free survival were observed between patients with low (, 25 ng/mL) and high ($ 25 ng/mL) VitD levels. 6 Besides its retrospective nature and patient heterogeneity, our study has two major limitations. First, it cannot be excluded that VitD deficiency is a surrogate marker for a more general micronutrient deficiency only reflecting overall health status. Second, as with all retrospective studies, our findings do not provide definite evidence of a causal relationship between VitD deficiency and posttransplant outcome. Further studies, prospective and preferably with an interventional design, are needed to confirm our findings. In addition, functional experiments dissecting the mechanism through which VitD influences both immunity and tumor biology are needed as well, hopefully providing insight into the mechanisms of VitD action in the setting of alloSCT.
VitD status represents an easily modifiable patient risk factor, and our results provide a rationale for the design of interventional studies. However, it should be noted that potential effects of other vitamins have not always been shown to be beneficial in clinical trials. 38 In our study and in several other studies on VitD status, median 25D3 levels ranged from 9 to 22 ng/mL. 6, 11, 30, 39 Consequently, and in accordance with clinical guidelines, selective repletion in patients with documented VitD deficiency should be favored rather than general supplementation. The optimal level of VitD is subject to debate. Commonly, serum 25D3 levels of 20 to 30 ng/mL and , 20 ng/mL are used to define insufficiency and deficiency, respectively. 3, 19, 20 However, it should be pointed out that these cutoffs were derived by studies on VitD and bone and overall health, and the optimal VitD level in the context of disease control is unknown. Taking into account the high prevalence of VitD deficiency in the transplant setting, we believe that applying too low a cutoff value for intervention (below the Institute of Medicine recommendation) may result in undertreatment with regard to both bone/overall health and potential disease control post-alloSCT. Nevertheless, it seems difficult in clinical trials to justify target doses below the general Institute of Medicine recommendations that suggest VitD levels . 20 ng/mL to meet the requirements of at least 97.5% of the population. 20 In summary, within the aforementioned limitations, our study suggests that VitD deficiency might affect disease control after alloSCT, in particular, in patients allografted for myeloid malignancies. However, the question of whether improving VitD status before alloSCT has an impact on outcome can only be answered by clinical trials.
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